Rita De Sanctis

Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial

Alessandro Gronchi, Stefano Ferrari, Vittorio Quagliuolo et al. · The Lancet Oncology · 2017 · 473 citations

Tumor Biology, Surgical Oncology, Malignant Disease +10

Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial

Eugenio Mercuri, Francesco Muntoni, Giovanni Baranello et al. · The Lancet Neurology · 2021 · 237 citations

Gene Therapies, Clinical Trials, Neurology +2

Functional changes in Duchenne muscular dystrophy

Elena Mazzone, Gessica Vasco, Maria Pia Sormani et al. · Neurology · 2011 · 168 citations

PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy

Lidija Antunovic, Rita De Sanctis, Luca Cozzi et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2019 · 145 citations

Adaptive Radiotherapy, Pet/ct Radiomics, Neoadjuvant Chemotherapy +10

Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group

Alessandro Gronchi, Silvia Stacchiotti, Paolo Verderio et al. · Annals of Oncology · 2016 · 126 citations · Full text

Surgical Oncology, Medicine, Metronomic Therapy +10